FDA Approves New mRNA Flu Vaccine for Adults Over 50

The mFlusiva vaccine marks the first use of mRNA technology to prevent influenza in older individuals.

Updated on Oct. 21, 2026 in Allergies

A close-up of a clear medical vial on a stainless steel surface, representing modern mRNA vaccine development. — The FDA has approved mFlusiva, the first mRNA-based influenza vaccine designed to provide enhanced immune protection for adults aged 50 and older. AI Illustration. Upload story photo >

Live Poll

Would you choose a new mRNA-based flu vaccine over a traditional flu shot for yourself?

The FDA has granted approval for mFlusiva, a new influenza vaccine specifically designed for adults over the age of 50. It is the first flu vaccine to utilize mRNA technology to trigger an immune response.

Why it matters

By utilizing mRNA technology, mFlusiva provides a more robust immune defense against the influenza virus compared to traditional vaccine methods. This development is aimed at improving protection for older populations as viral prevalence typically increases during colder months.

Clinical trial results show that mFlusiva is 26.6% more effective than traditional flu shots. The vaccine is currently restricted to individuals 50 years of age and older.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of vaccines and medical products.

The details

The vaccine functions by delivering synthetic genetic instructions that teach the body's cells to build harmless protein fragments. The immune system then trains against these fragments to prepare for potential exposure to the actual influenza virus.

The FDA granted formal approval for the mFlusiva vaccine in October 2026.

The Big Picture

The adoption of mRNA technology for influenza represents a major evolution in preventative medicine following the global rollout of mRNA-based COVID-19 vaccines. The approval of mFlusiva marks an expansion of the successful mRNA platform beyond the COVID-19 pandemic to target seasonal respiratory viruses.

Adults 50 and older may soon have access to a more effective vaccine option to protect against seasonal influenza. Potential recipients should be aware that common side effects include fatigue, muscle aches, and chills after vaccination.

The takeaway

This new vaccine offers a significant improvement in protection for older adults during flu season. Those eligible should consult with their healthcare provider to discuss how this mRNA-based option compares to their typical annual influenza shot.